With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers told us how they cope.
Both Eli Lilly and Company and Novo Nordisk have asked the US Food and Drug Administration to place their GLP-1 medications,a trade group, filed a lawsuit against the FDA , calling on it to restore tirzepatide to the shortage list after the FDA removed it on October 2, despite pharmacies still experiencing shortages, according to the association. The FDA isthe decision and won’t take action against compounders in the interim, with a joint status report scheduled for November 21.
He acknowledged none of these options solves “the problem of high costs and lack of insurance coverage.”In agreement is Caroline Apovian, MD, co-director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, Boston. When prescribing a compounded medication is necessary, it’s important for healthcare providers to know that the quality of the compounding pharmacies varies greatly, Stombaugh said. A prescriber needs to pick the compounding pharmacy, not the patient, and needs to vet it, she said, asking about protocols it follows for sterility and for chemical analysis, for instance.
When the brand name is back, how might a prescriber still write a prescription for a compounded version? “Compounded versions are typically compounded with something else,” Guarniere said.
Obese U.S. Food And Drug Administration United States Food And Drug Administration Fda Facial Insurance Practice Management Revenue Weight Management Board Certification Boards Board Recertification Louisiana Nurse Practitioner Virginia Vitamins Weight Loss Patient Safety Adverse Effects Side Effects Alabama Allergy Canada Canadian Chronic Disease Chronic Illness
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Battle Continues Over Compounded GLP-1sNovo Nordisk seeks to put a stop to semaglutide compounding, whereas the FDA agrees to allow compounding of tirzepatide, for now.
Read more »
Rise in GLP-1 RA and SGLT2 Inhibitor Prescribing in Patients With T1DAn analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.
Read more »
Study finds bariatric surgery declined with rise in GLP-1 drugs to treat obesityA new study has examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than doubled from 2022 to 2023.
Read more »
GLP-1s May Protect Against Progression to Cirrhosis in MASLDTaking a GLP-1 receptor agonist was associated with a lower risk for cirrhosis and related complications in patients with metabolic dysfunction–associated steatotic liver disease and diabetes.
Read more »
The Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster DrugNovo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical companies and compounders.
Read more »
The Diet Industry Is Reportedly in Total Meltdown Over GLP-1 Weight Loss DrugsScience and Technology News and Videos
Read more »